Aileron Therapeutics reports Q3 net loss of $5.8M; Phase 1b LTI-03 shows positive biomarker data

Rein Therapeutics, Inc.

2024-Q3 EPS reported -$1.31

Net loss of $5.8M ($0.27 per share) compared to $1.8M ($0.40) in Q3 2023; R&D expenses increased to $3.7M from $0.1M.
Cash and equivalents at $17.7M as of Sept 30, 2024, expected to fund operations into June 2025.
Phase 1b high-dose LTI-03 (5mg BID) in IPF showed dose-dependent biomarker effects; combined cohort data achieved statistical significance in 4 of 8 biomarkers.
Planning underway for Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis (IPF).
Exclusive option agreement with Advancium Health Network for ALRN-6924 (oncology) granted; non-refundable fee received, potential milestone and royalty payments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.